Introduction In clinical trials new oral anticoagulants (NOAC) have proved to be as effective
as warfarin for thromboprophylaxis in atrial fibrillation. The aim of this study was to evaluate …

Background Dabigatran is a direct thrombin inhibitor and an anticoagulant that is prescribed
to prevent ischemic stroke and systemic embolism in non-valvular atrial fibrillation …

Background: Warfarin has been used as the only oral anticoagulant for over 50 years in
patients with atrial fibrillation. Recently new oral anticoagulants like dabigatran, rivaroxaban …

Background: Prevention of thromboembolic complications is a priority in patients with atrial
fibrillation (AF). Based on the current guidelines, the role of vitamin K antagonists (VKA) in …

OBJECTIVE: Dabigatran is a nov-el target specific oral anticoagulant for stroke prevention in
non valvular atrial fibrillation. Little is still known about its real-world effectiveness and safety …

“Hot Topics.” Seminars in Thrombosis & Hemostasis last published “Hot Topics” issues in
late 20071 and early 2008. 2 Those issues were very popular with our readers, as identified …

Anticoagulation therapy is effective in preventing primary and secondary thromboembolic
events due to atrial fibrillation. Warfarin, which was approved by the United States in 1954 …

Introduction New oral anticoagulants are non-inferior compared with warfarin regarding
stroke prevention in atrial fibrillation, with similar or decreased risk of bleeding. However, it is …

There is a high prevalence of atrial fibrillation in the United States, particularly in the elderly
population. Patients with atrial fibrillation are at an increased risk of stroke and anticoagulant …

BACKGROUND: Warfarin had been the only oral anticoagulant for stroke prevention in
patients with atrial fibrillation (AF) for decades. Direct thrombin inhibitors and factor Xa …